

July 6, 2016



# **Interpace Diagnostics Announces Long-Term Outcomes Data for Cohort of 492 Patients**

## **Peer Reviewed Publication Further Demonstrates Clinical Utility of PancraGEN™**

PARSIPPANY, N.J., July 6, 2016 /PRNewswire/ -- Interpace Diagnostics Corp. (NASDAQ: IDYG), a company that provides clinically useful molecular diagnostic tests and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for better patient diagnosis and management, announced today the publication of a new article entitled "Management of Patients With Pancreatic Cysts: Analysis of Possible False-Negative Cases of Malignancy" appearing in the Journal of Clinical Gastroenterology, May/June edition. The goal of the study was to examine the utility of Interpace's Integrated Molecular Pathology (IMP) test PancraGEN® in making surveillance interval decisions for patients with pancreatic cysts. The results are based on long-term outcomes data of 492 patients followed for up to 7.7 years.

The authors included Gastroenterologists from Thomas Jefferson University, Georgetown University, University of Texas, Cleveland Clinic-Abu Dhabi, UAE, and several other private clinic sites. They concluded that "when used in the clinic, IMP is a useful diagnostic tool that aids in management of pancreatic cysts by limiting overtreatment and surveillance of inconsequential disease while enabling early detection of malignancy." Their analysis indicated that IMP can help guide management of pancreatic cysts by increasing confidence that observation is a safe, more appropriate management strategy in the majority of patients, allowing for longer surveillance intervals for patients regardless of cyst size. IMP also accurately identified patients at high risk for malignancy, even in small cysts, providing support for more aggressive management.

"This study demonstrates the utility of PancraGEN in the large majority of patients who have pancreatic cysts that will undergo surveillance rather than surgery. It adds to other recent publications regarding the influence of PancraGEN on surgery and surveillance management decisions in a real world setting and the favorable outcomes that can occur through those actions," said Jack Stover, President and CEO of Interpace.

### **About PancraGEN™**

PancraGEN™ is a pancreatic cyst molecular test that, by using a small sample of pancreatic cyst fluid, can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment. PancraGEN is 90% accurate, according to clinical studies, enabling effective risk stratification of patients. Pancreatic cancer is often difficult to diagnose in early stages and typically spreads rapidly with signs and symptoms appearing when the cancer is significantly

advanced. Because of this, and that complete surgical removal of the pancreas is not possible, pancreatic cancer is considered a leading cause of cancer deaths.

### **About Interpace Diagnostics Group, Inc.**

Interpace Diagnostics is a company that provides clinically useful molecular diagnostic tests and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for better patient diagnosis and management. The Company currently has three commercialized molecular tests; PancraGen® for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGenX, for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay and ThyraMIR, for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay. Interpace Diagnostics' mission is to provide personalized medicine through molecular diagnostics and innovation to advance patient care based on rigorous science.

### **Forward Looking Statements**

*This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, relating to our future financial and operating performance. The company has attempted to identify forward looking statements by terminology including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond company's control. These statements also involve known and unknown risks, uncertainties and other factors that may cause company's actual results to be materially different from those expressed or implied by any forward-looking statement. Known and unknown risks, uncertainties and other factors include, but are not limited to, our ability to adequately finance the business, the market's acceptance of our molecular diagnostic tests; our ability to secure additional business and generate higher profit margins through sales of our molecular diagnostic tests, in-licensing or other means, projections of future revenues, growth, gross profit and anticipated internal rate of return on investments. Additionally, all forward-looking statements are subject to the risk factors detailed from time to time in the Company's periodic filings with the Securities and Exchange Commission (SEC), including without limitation, the Annual Report on Form 10-K filed with the SEC on March 30, 2016.. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.*

### **CONTACTS:**

Interpace Diagnostics  
Investor Relations:  
Dave Schemelia  
EVC Group, Inc.  
(646)201-5431

[dave@evcgroup.com](mailto:dave@evcgroup.com)

Doug Sherk  
EVC Group, Inc.  
(646)445-4800  
[dsher@evcgroup.com](mailto:dsher@evcgroup.com)

To view the original version on PR Newswire, visit: <http://www.prnewswire.com/news-releases/interpace-diagnostics-announces-long-term-outcomes-data-for-cohort-of-492-patients-300294314.html>

SOURCE Interpace Diagnostics Group, Inc.